Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa dosing

besponsa dosing

Перейти к контенту

Главное меню:

besponsa dosing
Besponsa Dosage Guide - Drugs.com, Welcome to BESPONSA® | BESPONSA®, Besponsa - FDA prescribing information, side effects and uses, About BESPONSA® | BESPONSA®, Besponsa | European Medicines Agency, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Besponsa - Side Effects, Dosage, Interactions - Drugs , BESPONSA 1 mg powder for concentrate for solution for , Besponsa Intravenous : Uses, Side Effects, Interactions .
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 May 2019), Cerner Multum™ (updated 2 May 2019), Wolters Kluwer™ (updated 1 May 2019) and others.. Recommended Dosage. For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m 2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m 2 ), Day 8 (0.5 mg/m 2 ), and Day 15 (0.5 mg/m 2 ). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR). BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age..
Besponsa doses within a treatment cycle (i.e., Days 8 and/or 15) do not need to be interrupted due to neutropenia or thrombocytopenia, but dosing interruptions within a cycle are recommended for non-hematologic toxicities. If the dose is reduced due to Besponsa-related toxicity, the dose must not be re-escalated.. Males of reproductive potential should use effective contraception during treatment with BESPONSA and for at least 5 months after the last dose Are breastfeeding or plan to breastfeed. Avoid breastfeeding during treatment with BESPONSA and for at least 2 months after the final dose. Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL).. Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice. Inotuzumab ozogamicin is a monoclonal antibody linked to a chemotherapy drug. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy . The recommended BESPONSA dose was determined to be 1.8 mg/m 2 /cycle administered at a dose of 0.8 mg/m 2 on Day 1 and 0.5 mg/m 2 on Days 8 and 15 of a 28-day cycle with a dose reduction upon achieving CR/CRi..
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню